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Abstract
Background: The serine threonine kinase Pim-1 has documented roles in hematopoietic progenitor and
B cell precursor proliferation and survival. Pim-1 is a molecular target of the transcription factor Hoxa9.
Previous studies showed that Pim-1 deficiency phenocopied the hematopoietic progenitor defect in
hoxa9-/- mice and forced expression of Pim-1 normalized the in vitro proliferation defect inherent to
hoxa9-/- hematopoietic progenitors. Pim-1 is induced by cytokine signaling, including the early lymphoid/B
lineage regulators Flt3 and IL-7, and expression levels were shown to influence the size of the B cell
compartment in bone marrow (BM).
Results: In this study, we sought to determine if transgenic expression of Pim-1, driven by the
immunoglobulin enhancer, Eμ, was sufficient to rescue the lymphoid/B cell precursor defect in hoxa9 or
flt3-ligand (flt3l) deficient mice. Unexpectedly, expression of Eμ − Pim1 exacerbated lymphoid progenitor
deficiencies in flt3l-/-, and to a lesser extent, hoxa9-/- mice. Furthermore, Eμ − Pim1 expression alone
reduced early myeloid and lymphoid, but not erythroid, progenitors. In contrast, Pim-1 deficiency had no
significant effect on early lymphoid/B cell development through the Pre-Pro-B cell stage, but caused a
significant reduction in IgM− B cell precursors. Importantly, loss of Pim-1 did not phenocopy hoxa9- or
flt3l-deficiency on the lymphoid/early B cell progenitor pools.
Conclusions: These experimental findings demonstrate that Pim-1 overexpression has developmental-stage-specific
effects on B lymphopoiesis and myelopoiesis. Importantly, these suggest that Pim-1 deficiency does not
contribute significantly to the early lymphoid/B cell developmental deficiency in hoxa9-/- or flt3l-/- mice.
Keywords: B cell precursors, Eμ-Pim1 transgene, pim1-/-, Flt3, Hoxa9, B cell development, Lymphopoiesis,
Hematopoiesis
Background
The steady-state production of B lineage lymphocytes in
bone marrow is contingent on the developmental-stage-
specific expression and combinatorial activities of multiple
regulatory proteins including transcription factors, signal-
ing molecules, microRNAs, and epigenetic modifiers. A
critical early event in B cell development is lymphoid
lineage specification within the multipotential progenitor
(MPP) pool which we and others have shown is dependent,
in part, on the homeodomain transcription factor Hoxa9
and signaling via the receptor tyrosine kinase Flt3 [1–4].
Germline knockout of Hoxa9 or Flt3-ligand largely
phenocopy each other with respect to reductions in
numbers of MPPs, the lymphoid progenitor subsets
ALP and BLP, and B cell precursors in BM. Import-
antly, Hoxa9 and Flt3 signaling function synergistic-
ally to regulate a critical early checkpoint in lymphoid
development, as combined loss of Hoxa9 and Flt3
signaling ablates the generation of lymphoid primed
multipotential progenitors [4].
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Pim-1 is a member of the Pim family of proto-
oncogenes that encode a distinct class of serine/threo-
nine kinases. Pim-1 was originally identified as a target
for proviral activation in Moloney murine leukemia virus
induced T cell lymphomas [5]. PIM proteins are widely
expressed in most tissues and co-expression of family
members has been found in various tissues [6]. The
transcription of Pim family members is induced by a
variety of cytokines and mitogens that transduce their
primary signal through the JAK/STAT pathway [7]. A
role for Pim-1 in B cell development was previously
demonstrated through analysis of pim1-/- and Eμ-Pim1
transgenic mice [8, 9]. Pim1-/- Pre-B cells exhibited
impaired in vitro proliferation in response to IL-7 and
stem cell factor (SCF) that was rescued by expression of
a functional Pim-1 transgene [10]. In contrast, ove-
rexpression of Pim-1increased numbers of IL-7 + SCF
responsive B cell colonies. These combined data pro-
vided the first evidence that Pim-1 was an important
regulator of B lymphopoiesis in mice, and linked Pim-1
to the IL-7R signaling pathway.
Cytokine signaling plays an essential role in early
lymphoid/B cell development. Threshold levels of Flt3
signaling are required for the proliferation, survival, and
maintenance of MPPs competent to generate B cell
precursors [1, 11]. Flt3 signaling is mediated by the Ras
and STAT5 pathways [12]. A dominant negative form of
Ras was shown to phenocopy the B lineage developmen-
tal block in flt3-/- mice, impairing the proliferation of
common lymphoid progenitors and Pre-Pro-B cells. The
same study showed that Ras promoted STAT5-dependent
Pro-B differentiation by enhancing expression of IL-7Rα
[12]. Pim-1 is induced downstream of Jak2/STAT5 signal-
ing and has also been implicated in playing a role in the
proliferation and/or differentiation of myeloid progenitors
[13–15]. Importantly, a role for Pim-1 in regulation of the
early lymphoid/B cell progenitor pool, prior to expression
of CD45R/B220, has not been reported.
Functional studies have confirmed a role for Pim-1 in
regulating hematopoietic stem cell (HSC) proliferation
and survival. HSCs from pim1-/- mice exhibited im-
paired repopulating capacity in competitive transp-
lantation experiments [16]. In vitro assays revealed
decreased cytokine mediated cell growth and differenti-
ation of hematopoietic progenitors [7]. In contrast, over-
expression of human Pim-1 driven by vav hematopoietic
regulatory elements and SV40 showed enhanced
hematopoietic progenitor function in vitro and in vivo
[16]. The hematopoietic defects exhibited by pim1-/-
mice are strikingly similar to those in hoxa9-/- mice as
loss of hoxa9 also impaired the proliferation and re-
populating ability of HSCs [17]. Consistent with this
observation, pim1 is a direct target of Hoxa9 [18].
Somatic ablation of pim1, hoxa9, or flt3 causes select
reductions in hematopoietic progenitor subsets and B
cell precursors. However, an obligate role for Pim-1 in
regulation of lymphoid and/or early B cell development
has not been investigated. In this study we evaluated the
role of Pim-1 in murine lymphoid lineage specification
and B cell development through comparative flow
cytometric analysis of hoxa9-/- x Eμ-Pim1Tg, flt3l-/- x
Eμ-Pim1Tg, Eμ-Pim1 transgenic, pim1-/-, hoxa9-/-, and
flt3l-/- mice. Our experimental findings revealed that
Pim-1 dysregulation has developmental-stage-specific
effects on B lymphopoiesis and early myeloid, but not
erythroid progenitors. Furthermore, we show that Pim1-
deficiency is not the basis of the lymphoid or early B cell
developmental defects in hoxa9-/- or flt3l-/- mice.
Methods
Mice
Wildtype C57Bl/6 mice were generated from our breed-
ing colony. Pim1-/- and Eμ − Pim1 transgenic mice have
been previously described [10]. Pim1-/- mice were pro-
vided by Andrew S. Kraft and Eμ − Pim1 transgenic mice
were provided by Jung-Hyun Park and permission for
both obtained from A. Berns. All mice evaluated in this
study were 8–12 weeks of age. C57Bl/6, EμPim-1Tg,
hoxa9-/- x Eμ-Pim1Tg, and flt3l-/- x Eμ-Pim1Tg mice
were bred in the Mayo Clinic animal facility, and all
animal experiments detailed in this study were con-
ducted under guidelines established and approved by the
Mayo Clinic Institutional Animal Care and Use Com-
mittee. PCR, using DNA isolated from tail clips, was
performed using previously published primers to confirm
the genotype of compound mice [19, 20].
Flow cytometric analysis of BM hematopoietic progenitor
subsets and B cell precursors
Methods for flow cytometry and progenitor isolation
have been described [4]. Flow cytometric analysis was
performed on the FACS-Canto or LSRII cytometers (BD
BioSciences, San Jose, CA) and data analysis performed
with FlowJo software (Tree Star, Ashland, OR). All
antibodies used in this study were purchased from
eBioScience or Biolegend. HSC/MPPs were resolved
using the following combinations of antibodies: Lineage
positive APC cocktail (CD3ε, Ter119, B220, Mac-1, Gr-
1), CD34 FITC, Flt3 PE, Sca-1 PerCP-Cy5.5, CD150 PE-
Cy7, c-kit APC-eflour 780 and 1.5×106 million events
collected for the analysis. MEPs, CMPs, and GMPs were
resolved using the following combinations of antibodies:
Lineage positive APC cocktail (CD3e, Ter119, B220,
Mac-1, Gr-1), CD34 FITC, Flt3 PE, Sca-1 PerCP-Cy5.5,
c-kit APC-eflour 780 and 1.5 × 106 million events
collected for the analysis. ALP and BLP were resolved
using the following combinations of antibodies: Lineage
positive FITC cocktail (CD3ε, CD8α, CD11c, NK1.1,
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Ly6C, Ter119, B220, Mac-1, Gr-1), Flt3 PE, IL-7R PE-
Cy7, Ly6D AF647, c-kit APC-eflour 780, PDCA1 PerCP-
eflour 710 and 2×106 million events collected for the
analysis. Pre-Pro-B and BCP subsets were resolved using
the following combinations of antibodies: B220 FITC,
AA4.1 PE, PDCA1 PerCP-eflour 710, CD19 Pe-Cy7,
Ly6D AF647, and IgM APC-Cy7 and 500,000 to 1 × 106
million events collected for the analysis. Red blood cells
and cellular debris were excluded from the analysis with
mononuclear cell and doublet exclusion gates. Absolute
cell numbers were determined by multiplying population
frequencies (total subset event count divided by total
event count) times mononuclear cell count. Cell counts
reflect numbers of cells per 4 hindlimb leg bones.
Realtime RT-PCR analysis of pim1 transcript levels in bone
marrow progenitor subsets
Hematopoietic progenitor subsets were purified by cell
sorting for RNA isolation, cDNA synthesis, and qPCR
analysis as we previously described [21]. HSC/MPP were
purified as Lin− (see Lin+ cocktail above) c-kithi Sca-1+
Flt3-lo, LMPP as Lin− c-kithi Sca-1+ Flt3hi, CLP as Lin−
c-kitlo IL-7R+ Sca-1+ Flt3+, Pre-Pro-B as B220+ CD43+
CD19− IgM− (which includes a mix of Pre-Pro-B, NK,
and pDCs), Pro-B as B220+ CD43+ CD19+ IgM−, Pre-B
as B220+lo CD43− CD19+ IgM−, and IgM+ as B220+hi
CD43− CD19+ IgM+. Realtime PCR was performed using
a pim1 taqman probe (Mm00435712_m1) and gene ex-
pression normalized to 18S RNA. All cDNA samples
were assayed in triplicate. Relative transcript abundance
was determined using the 2-ΔΔCT method.
Statistics
Statistical significance was determined using the Stu-
dent-t test. Data are reported as standard error of
the mean (SEM) and p-values less than 0.05 were
considered significant.
Results
Forced expression of Pim-1 does not rescue the lymphoid/B
lineage deficiency in hoxa9-/- or flt3l-/- mice
Gene-targeted ablation of pim1, hoxa9, or flt3 causes
reductions in select hematopoietic progenitor subsets
and B cell precursors. Pim-1 is a molecular target of
Hoxa9 and has been shown to be induced by Flt3 signal-
ing [18, 22]. To determine if dysregulated expression of
Pim-1 contributed to the lymphoid/B lineage precursor
deficiency in hoxa9-/- or flt3l-/- mice, hoxa9-/- x Eμ-
Pim1Tg and flt3l-/- x Eμ-Pim1Tg mice were generated.
Transgenic expression of Eμ-Pim1 had no significant
effect on BM cellularity in hoxa9-/- or flt3l-/- mice (data
not shown). Hoxa9-/- and flt3l-/- mice have significantly
decreased numbers of Lin− c-kitlo IL-7R+ common lymph-
oid progenitors (CLPs) [4]. CLPs can be fractionated into
Lin− PDCA1− IL-7R+ c-kitlo Flt3+ Ly6D− all lymphoid
progenitors (ALP) and Lin− PDCA1− IL-7R+ c-kitlo Flt3+
Ly6D+ B lymphoid progenitors (BLP) [23]. Eμ transgene
driven expression of Pim-1 did not exacerbate the
deficiencies in ALP or BLP in hoxa9-/- mice (Fig. 1a–c).
However, Eμ-Pim1Tg expression did exacerbate the reduc-
tions in ALP and BLP in flt3l-/- mice (Fig. 1a–c). Expres-
sion of B220 distinguishes Pre-Pro-B cells from BLP [23].
Consistent with reductions in ALP and BLP, numbers of
PDCA1− Ly6D+ B220+ CD19− Pre-Pro-B cells were
reduced in hoxa9-/- x Eμ-Pim1Tg and flt3l-/- x Eμ-
Pim1Tg mice compared to WT (Fig. 2a–b). However, in
contrast to ALP and BLP, Eμ-Pim1Tg expression did not
abrogate the Pre-Pro-B cell deficiency hoxa9-/- or flt3l-/-
mice (Fig. 2a–b). The B lineage committed progeny of
Pre-Pro-B cells are IgM− B220+ CD19+ B cell precursors
(BCPs). Unlike the negative impact of Eμ-Pim1 transgene
expression on CLP subsets and Pre-Pro-B cells, no statisti-
cally significant reduction in IgM− B220+ CD19+ BCPs or
total IgM+ B cells was found in hoxa9-/- x Eμ-Pim1Tg
(Fig. 2a,c–d). However, reductions in IgM− B220+ CD19+
BCP and total IgM+ B cell compartments were maintained
in flt3l-/- and flt3l-/- x Eμ-Pim1Tg mice (Fig. 2a,c–d).
These data reveal a previously uncharacterized inhibitory
effect of Eμ-Pim1Tg expression on early lymphoid/B cell
development.
Impact of Pim1-deficiency versus Eμ − transgene driven
expression of Pim-1 on BM lymphoid progenitors and
BCPs
A role for Pim-1 in B cell development was previously
demonstrated from analysis of pim1-/- and Eμ-Pim1
transgenic mice [10]. Our findings that Eμ transgene
driven expression of Pim-1 abrogated lymphoid/early B
cell development supported further evaluation of the
effects of dysregulated expression of Pim-1 on develop-
ment of this lineage. BM cells from WT, pim1-/-, and
Eμ-Pim1 transgenic mice were stained with combina-
tions of antibodies to resolve ALP, BLP, Pre-Pro-B, IgM−
BCP, and IgM+ B cells. Comparison of BM mononuclear
cell counts revealed no significant difference between
WT and Eμ-Pim1 transgenic mice, but a statistically sig-
nificant reduction in pim1-/- mice (5.2×107 ± 0.33, n = 3;
p = 0.0055) compared to WT (7.9 ×107 ± 1.3, n = 10). No
statistically significant alterations in absolute numbers of
ALP, BLP, or Pre-Pro-B were identified between WT and
pim1-/- mice (Fig. 3a). The inverse was found in Eμ-
Pim1 transgenic mice wherein absolute numbers of
phenotypic ALP, BLP, and Pre-Pro-B cells were signifi-
cantly reduced compared to WT (Fig. 3a). Finally, while
numbers of IgM− BCP and IgM+ B cells in Eμ-Pim1
transgenic mice were comparable to WT (Fig. 3a), we
found that IgM−, but not IgM+, BCPs were reduced in
pim1-/- mice [10]. CD19+ IgM− BCPs constitute Pro-B
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and Pre-B cells. To gain further insight into the role of
Pim-1 in hematopoietic development and B cell differen-
tiation, we evaluated pim-1 transcript levels in purified
bone marrow progenitor subsets. As shown in Fig. 3b,
abundant pim-1 transcript expression was high ex-
clusively in Pre-B cells across the B lineage developmen-
tal spectrum. Taken together, these data suggest that
elevated levels of Pim-1 are inhibitory for lymphoid/B
cell development prior to commitment to the B cell fate.
On the other hand, loss of Pim-1 decreased IgM− Pro-B/
Pre-B cells, suggesting an essential role at this stage.
Impact of Pim1-deficiency versus Eμ − transgene driven
expression of Pim-1 on HSC, MPP, and erythroid/myeloid
progenitors
The Eμ enhancer is active very early in hematopoiesis,
within LSK+ MPPs [11, 24]. A previous study reported
increased numbers of LSK+ cells in vav-Pim1Tg mice,
a b
c
Fig. 1 Forced expression of Pim-1 does not rescue the lymphoid deficiency in hoxa9-/- or flt3l-/- mice. a Flow cytometry profile and gating
strategy for ALP and BLP in the various mouse strains. b Bar graph depicting absolute numbers of ALP in the various mice. c Bar graph depicting
absolute numbers of BLP in the various mice. Data represents the mean ± SEM of 4–10 mice per group. A single asterisk * denotes p < 0.05 and
** denotes p < 0.005. To determine statistical significance, comparisons were made to WT, or between select comparators indicated by the line





Fig. 2 Effect of Eμ-Pim1Tg expression on B cell subsets in bone marrow. a Flow cytometric analysis of Pre-Pro-B, CD19+ cells, IgM-lo B cells (which
includes BCPs and recirculating B cells), and IgM+hi naïve B cells in the various mouse strains. b-e Graphs depicting absolute numbers of
(b) Pre-Pro-B cells, (c) CD19+ cells, (d) IgM-lo B cells, and (e) IgM+ BCPs. Data represents the mean ± SEM of 4–10 mice per group. * denotes
p < 0.05 and ** denotes p < 0.005
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but a similar analysis has not been reported for Eμ-
Pim1Tg mice [16]. To begin, we compared frequencies
of LSK+ cells. In contrast to results reported for vav-
Pim1Tg mice, frequencies and numbers of total LSK+
cells were significantly reduced in Eμ-Pim1Tg mice
(Fig. 4a–b and data not shown). Next we compared
frequencies and numbers of LSK+ CD150+ CD34− HSC
and LSK+ CD150− Flt3+ MPP in Eμ-Pim1Tg mice.
Absolute numbers of HSC and MPP were significantly
reduced in Eμ-Pim1Tg mice (Fig. 4c–d). However, the
reduction was attributed to the total decrease in LSK+
cells as percentages of CD150+ CD34− HSC within the
LSK+ compartment were increased in Eμ-Pim1Tg mice
(6.23 ± 0.990 vs. 4.05 ± 1.07 %, p = 0.014, in Eμ-Pim1Tg
vs. WT, respectively). The same was true for the re-
duction in absolute numbers of MPP as percentages
CD150− Flt3+ within the LSK+ compartment was not sig-
nificantly reduced (73.7 ± 4.53 vs. 80.1 ± 3.72 %, p = 0.064,
in Eμ-Pim1Tg vs. WT, respectively). The reduction in
LSK+ cells in Eμ-Pim1Tg mice could influence num-
bers of erythroid/myeloid progenitors. Frequencies of
Lin− ckithi Sca1− cells were not altered in Eμ-Pim1Tg
mice (Fig. 4a). However, significant alterations in fre-
quencies and absolute numbers of CMP and GMP,
but not MEP, were documented Eμ-Pim1Tg mice
(Fig. 4a,e–m). No significant alterations in frequencies
or numbers of LSK+, HSC, MPP, CMP, MEP, or GMP
were observed in pim1-/- mice, compared to WT (Fig. 4).
Taken together, these data show that Eμ-Pim1Tg driven
expression of Pim-1, but not Pim1-deficiency, reduces
the myeloid but not the erythroid/megakaryocytic
progenitor pools.
Loss of Pim-1 does not phenocopy hoxa9- deficiency on
the lymphoid/early B cell progenitor pools
Pim-1 is a Hoxa9 target gene and forced expression of
Pim-1 rescued the in vitro proliferation of hoxa9-/- BM
progenitors [18]. We reasoned that if Pim1-deficiency is
a b
Fig. 3 Impact of Eμ-Pim1Tg or Pim1-deficiency on lymphoid progenitor and B cell precursor subsets in bone marrow. a Bar graphs depicting
absolute numbers of ALP, BLP, Pre-Pro-B, IgM− B cell precursors, and IgM+ B cells. Data represents the mean ± SEM of 3–10 mice per
group. * denotes p < 0.05 and ** denotes p < 0.005. b Realtime PCR analysis of pim-1 transcript levels in sorted hematopoietic progenitor
and B cell subsets with HSC/MPP designated as the comparator





Fig. 4 (See legend on next page.)
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the basis of the hematopoietic progenitor defect in
hoxa9-/- mice, then pim1-/- mice should phenocopy, at
least in part, hoxa9-/- progenitor defects in BM.
Hoxa9-/- and pim1-/- mice shared statistically signifi-
cantly increased frequencies of HSCs. However, while
hoxa9-/- and flt3l-/- mice shared similar reductions in
CMP, GMP, ALP, BLP, and Pre-Pro-B cells, consistent
with our previous observation, loss of Pim-1 did not
phenocopy Hoxa9-deficiency (Fig. 5) [4, 23].
Discussion
Previous studies have implicated a role for Pim-1 in
regulation of B cell development in BM and pim-1 is a
Hoxa9 target gene [10, 18]. Furthermore, hoxa9- and
pim1-deficient mice share similar hematopoietic pheno-
types and forced expression of Pim-1 rescued the in
vitro proliferation defect in hoxa9-/- BM progenitors
[17, 18]. To determine if forced expression of Pim-1 was
sufficient to restore the lymphoid progenitor/B cell
precursor defect in hoxa9-/- or flt3l-/- mice, we gener-
ated hoxa9-/- Eμ-Pim1Tg mice and flt3l-/- Eμ-Pim1Tg
mice. Unexpectedly, Eμ driven expression of Pim-1
exacerbated the deficiencies in ALP and BLP in flt3l-/-,
but not hoxa9-/- mice. The detrimental effect in flt3l-/-
Eμ-Pim1Tg mice was specific to the ALP and BLP stages
of B cell differentiation, as the Eμ-Pim1Tg did not
further exacerbate the B cell deficiencies in flt3l-/- mice
from the Pre-Pro-B through the IgM+ stages. The nega-
tive effect of Eμ-Pim1Tg expression was not restricted to
the ALP and BLP compartments. We previously showed
that Eμ is active from a very early stage in hematopoiesis
and here we also show that Eμ-Pim1Tg expression
caused significant reductions in numbers of HSCs,
MPPs, CMPs, and GMPs suggesting that Pim-1 expres-
sion levels must be carefully controlled during early
hematopoietic differentiation [11, 24]. In contrast, loss
of Pim-1, which we hypothesized might have deleterious
consequences on the early lymphoid/B cell progenitor
pools, was dispensable for hematopoiesis with the exception
of IgM− BCPs [10]. Consistent, with our findings, realtime
PCR of pim-1 transcription across the hematopoietic
spectrum, showed significant levels limited to BCPs at
the Pre-B cell stage. Finally, through direct comparative
hematopoietic progenitor subset analysis of hoxa9-/-,
(See figure on previous page.)
Fig. 4 Impact of Eμ-Pim1Tg or Pim1-deficiency on primitive hematopoietic and myeloid-erythroid progenitor subsets in bone marrow. a Flow
cytometry profile and gating strategy for HSC, Flt3+ MPP, CMP, GMP, and MEP. Bar graphs depict absolute numbers or frequencies of the various
progenitor subsets. b Percentage of LSK+ in total BM. c–d Absolute number of HSC or MPP in BM. e–g Frequencies of CMP, MEP, or GMP within
the Lin- ckithi Sca1- subset. h–j Absolute numbers of CMP, MEP, or GMP in BM. k–m Frequencies of CMP, MEP, or GMP in BM. Data represents
the mean ± SEM of 3–10 mice per group. * denotes p < 0.05 and ** denotes p < 0.005
Fig. 5 Comparison of Hoxa9-, Fl3tl-, and Pim1-deficiencies on hematopoietic progenitor subsets and Pre-Pro-B cells. Bar graphs depict absolute
numbers of the various progenitor subsets. Data represents the mean ± SEM of 3–4 mice per single knockout and 10 WT mice. * denotes p < 0.05
and ** denotes p < 0.005
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flt3l-/-, and pim1-/- mice, we suggest that loss of Pim-1 is
unlikely to contribute significantly to the hematopoietic
progenitor defects in either hoxa9-/- or flt3l-/- mice.
Taken together, these comprehensive flow cytometric ana-
lyses demonstrate very select lineage and developmental-
stage-specific consequences of dysregulated expression of
Pim-1 expression on BM hematopoietic progenitor and B
lineage subsets.
The serine threonine phosphokinase Pim-1 is highly
expressed in hematopoietic cells in mouse and man
[20, 25]. The pim-1 gene was originally discovered as
a common insertion site in MoMuLV-induced T cell
lymphomas and later found in B-cell lymphomas and
erythroleukemias. Overexpression of Pim-1 driven by
the Eμ enhancer was shown to lead to a low inci-
dence of T cell lymphomas and increased sensitivity
to chemically induced T cell transformation. In the B
lineage, overexpression of Eμ − Pim-1 facilitated estab-
lishment of B cell progenitor cell lines blocked at the
Pre-B cell stage of differentiation [10]. The same
study reported that marrows with the highest Pim-1
expression had a reduction in M-CSF responsive cells,
and suggested the result could be due to impaired
macrophage differentiation or on a macrophage pro-
genitor. Our immunophenotypic analysis of Eμ-Pim1
transgenic mice provides insight into the reductions
in M-CSF responsive cells as we identified significant
reductions in frequencies and absolute numbers of
CMP and GMP.
PIM kinases are short-lived proteins induced at the
level of transcription upon mitogenic stimulation [26].
They do not have regulatory domains and are constitu-
tively active when expressed. Under physiologic condi-
tions, their short half-life limits their activity [27]. Many
cytokines that induce pim gene transcription act through
the JAK/STAT pathway. The pim1 promoter has binding
sites for STAT3 and STAT5 [28, 29]. Pim-1 protein then,
in turn, functions to inhibit the JAK/STAT pathway by
binding and activating SOCS proteins [30]. SOCS pro-
teins support cytokine signaling through the Ras/MAPK
pathway by binding the Ras inhibitor RasGAP [30].
Interestingly, dysregulated Ras/SOCS function mediated
by overexpression of Pim-1 provides a plausible cellular
mechanism for the impaired lymphoid/early B lineage
development exhibited by Eμ − Pim1Tg mice. Ras proteins
are involved in regulating proliferation and differentiation
of various cell types in a tissue specific manner. Pertinent
to this study, mice expressing a dominant negative form
of human H-Ras have a severe block in B cell develop-
ment at the Pre-Pro-B to Pro-B transition [31]. Li, et al.,
previously showed that a Flt3/Ras dependent signal gov-
erns lymphoid progenitor (ALP + BLP) and Pre-Pro-B
proliferation [12]. In addition, they showed that Flt3/Ras
suppresses expression of socs2 and socs3. They concluded
that Flt3 activation of Ras primes B cell development by
inducing a state of STAT5 responsiveness, a key event
downstream of IL-7R signaling in lymphoid progenitors
leading to induction of the B cell fate specification and
commitment factor EBF1. Sustained expression of Pim-1
would be predicted to stabilize SOCS expression, impair-
ing STAT5-mediated induction of ebf1, suppressing EBF1-
directed B cell differentiation. Indeed, this hypothetical
molecular explanation is consistent with our findings that
the Flt3 dependent ALP and BLP stages are exquisitely
sensitive to dysregulated Pim-1 in flt3l-/- mice. It also
suggests that it is unlikely that elevated levels of Pim-1 are
inhibitory for lymphoid/B cell development by accelerat-
ing B cell differentiation, given the critical role for STAT5/
EBF1 in this process.
Pim kinases act as oncogenes by promoting cell cycle
progression by phosphorylating and down-regulating the
cyclin dependent kinase inhibitor p27Kip1. Pim kinases
also have the ability to suppress p27kip1 transcription
through phosphorylation and inactivation of forkhead
transcription factors, including FoxO1 and FoxO3 [32].
Pim-1 inactivation of FoxO1 would have deleterious
effects on B cell fate determination as FoxO1 is an
integral member of a global network of transcription
factors, including E2A and EBF1 [33]. Importantly,
FoxO1-deficient mice also have an arrest in B cell
development at the CLP stage, specifically at the BLP
stage, and phenocopy EBF1-deficiency [34]. Importantly,
FoxO1-deficient BLPs have increased transcripts for
socs2, reminiscent of Pim-1 overexpression [30]. Based
on our immunophenotyping results, together with previ-
ous phenotypic, molecular, and cellular data in the litera-
ture database, we hypothesize that dyregulated expression
on Pim-1, driven by Eμ, impairs lymphoid/early B cell
differentiation through upregulation of SOCS proteins
and inactivation of FoxO1. Upregulation of SOCS proteins
inhibits STAT5 mediated B cell differentiation leading to
upregulation of EBF1. Inactivation of FoxO1 impairs the
global transcriptional network orchestrated by E2A, EBF1,
and FoxO1 that directs the early program of B lineage
gene expression, requisite for B cell differentiation. In
contrast, loss of Pim-1, would be predicted to suppress
SOCS protein expression and stabilize FoxO1, favoring B
cell developmental potential, providing an explanation for
the slight, but not statistically significant, increase in BLP
and Pre-Pro-B cells we observed in pim1-/- mice. We note
that additional studies are required to determine if this
molecular explanation is valid.
The goal of this project was to investigate the role of
Pim-1 in early lymphoid/B cell development. However,
we also found reductions in numbers of HSC, MPP,
CMP, and GMP in Eμ − Pim1Tg mice. An, et al., re-
ported an increase in frequencies and numbers of LSK+
cells in vav-Pim1Tg mice, whereas we report decreased
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frequencies and numbers of LSK+ cells in Eμ − Pim1Tg
mice [16]. The overall decrease in LSK+ cells was the
basis of the decreased numbers of HSCs and MPPs,
as frequencies of CD150+ CD34− immunophenotypic
HSC within the LSK+ compartment were actually
increased in Eμ − Pim1Tg mice. We believe it unlikely
that Eμ − Pim1Tg expression has any functional conse-
quence on HSC biology for two reasons. First, we previ-
ously showed that Eμ driven reporter expression is
confined to CD27+ MPPs within the LSK+ compartment
and HSCs are CD27− [11, 24, 35]. Second, the frequencies
of CD150+ CD34− HSCs were substantially increased in
Eμ − Pim1Tg mice.
The cellular and/or molecular basis of the inhibitory con-
sequence of Eμ − Pim1Tg expression on numbers of Flt3+
MPPs in noteworthy, as Flt3+ MPPs are the precursors of
CMP and CLP and these hematopoietic subsets were the
most sensitive to Eμ − Pim1Tg expression. Eμ − Pim1Tg
expression did not impact Flt3+ CMP or CLP by altering
the expression levels of Flt3. However, Flt3+ CMP and CLP
were particularly sensitive to Eμ − Pim1Tg expression.
These findings suggest that overexpression of Pim-1 might
negatively impact signaling networks downstream of Flt3
stimulation in Flt3+ progenitor subsets, impairing either
their proliferation or survival. Regardless of the mechanism,
differentiating CMP and CLP overcome the inhibitory
effects and their downstream progeny are refractory to
sustained expression of Pim-1. Overexpression of Pim-1 in
myeloid progenitors is likely limited by inactivation of Eμ
due to lack of expression of critical activators necessary to
maintain enhancer activity. It is interesting to note that
Pim-1 driven by vav regulatory elements was low in mature
myeloid cells [16].
Finally, although our flow cytometry analysis revealed
that Pim1-deficiency does not provide a molecular explan-
ation for the lymphoid/B cell deficiency in hoxa9-/- mice,
pim1-/- and hoxa9-/- mice do share similar phenotypic and
functional HSC defects. These observations and reported
findings underscore developmental stage specific require-
ments for Hoxa9 and Pim-1 in hematopoietic development.
Conclusions
The goal of this study was to determine the requirement
for Pim-1 in early lymphoid/B cell development. We
show that controlled expression of Pim-1 is important in
lymphoid/B cell development. High levels of Pim-1 are
inhibitory while Pim-1 is dispensable for establishment
of lymphoid progenitor and Pre-Pro-B cell pools.
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